Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2022 Feb 15;327(7):678-680.
doi: 10.1001/jama.2022.0210.

Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

Lindsey Wang  1 , Pamela B Davis  2 , David C Kaelber  3 , Nora D Volkow  4 , Rong Xu  1
Affiliations
Comparative Study

Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period

Lindsey Wang et al. JAMA. .

Abstract

This study examines breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in March-August 2021, when the Delta variant predominated, among a general US cohort vaccinated with mRNA-1273 or BNT162b2.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Davis reported receiving grants from the National Institutes of Health outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Monthly Incidence Rates of Breakthrough SARS-CoV-2 Infections From July to November 2021 in 2 Cohorts
The mRNA-1273 cohort comprised fully vaccinated individuals receiving 2 doses of mRNA-1273 vaccine anytime between December 2020 and November 2021 but who had no booster shot and no prior SARS-CoV-2 infection. The BNT162b2 cohort was similar to the mRNA-1273 cohort but comprised individuals receiving BNT162b2 vaccine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Collier AY, Yu J, McMahan K, et al. . Differential kinetics of immune responses elicited by Covid-19 vaccines. N Engl J Med. 2021;385(21):2010-2012. doi:10.1056/NEJMc2115596 - DOI - PMC - PubMed
    1. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533-1535. doi:10.1001/jama.2021.15125 - DOI - PMC - PubMed
    1. Self WH, Tenforde MW, Rhoads JP, et al. ; IVY Network . Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention . COVID Data Tracker variant proportions. Accessed December 8, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
    1. Centers for Disease Control and Prevention . COVID-19 and people with certain medical conditions. Accessed December 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-...

Publication types

Supplementary concepts